Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
49 hedge funds and large institutions have $58.1M invested in Regulus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 48 → 49 (+1)
5.7% less ownership
Funds ownership: 59.48% → 53.78% (-5.7%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
63% less capital inflows, than outflows
Capital inflows: $4.3M | Capital outflows: $11.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.2M |
| 2 |
BVF Inc
San Francisco,
California
|
+$1.08M |
| 3 |
Ascend Capital
Orinda,
California
|
+$1.07M |
| 4 |
Laurion Capital Management
New York
|
+$414K |
| 5 |
DRW Securities
Chicago,
Illinois
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$6.55M |
| 2 |
Broadfin Capital
New York
|
-$2.94M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$543K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$433K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
-$255K |
RGLS Hedge Fund Activity: Q4 2017 in Review
49 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2017, worth a combined $58.1M — down 25% from $77.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RGLS positions and 9 closed out — a net gain of 1 holder — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.55M sold.
- 49 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2017, up from 48 in Q3 2017.
- Funds reported $58.1M of Regulus Therapeutics stock for Q4 2017, down 25% quarter-over-quarter.
- 10 funds opened new Regulus Therapeutics positions in Q4 2017 and 9 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q4 2017 was Point72 Asset Management, an estimated $1.2M added.
- The largest Regulus Therapeutics seller in Q4 2017 was EcoR1 Capital, an estimated $6.55M sold.
Based on aggregated 13F filings for Q4 2017.